G1 THERAPEUTICS, INC.
Small molecule CDK4/6 inhibitors that induce pharmacological quiescence in hematopoietic stem cells to protect against chemotherapy-induced myelosuppression
- Sector
- Biotech
- Headquarters
- RESEARCH TRIANGLE PARK, NC
- Founded
- 2008
- Latest Form D
- $47M, May 2016
- Total capital
- $71.6M
- Federal grants
- $522K
- 1 award · 2015
- Rank in peer group#230 of 502
- Private capital raised
- $71M
- 5 Form D · last May 2016
- 126 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 29
- 11 pending · first 2019
- Rank in peer group#2 of 502
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$47M
- Federal grantHealth and Human S · Phase II · Development of GZ38-1, a Novel Protectant of Chemotherapy-Induced Myelosuppressio$522K
- Private capital raisedForm D · SEC · 4th filing$16.5M
- Private capital raisedForm D · SEC · 3rd filing$6.3M
- Private capital raisedForm D · SEC · 2nd filing$458K
- Private capital raisedForm D · SEC · 1st filing$763K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#230 · top 46%
- Granted patents#2 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Carol A. WebbDirectorNamed in SEC Form D filings
- Christy A. ShafferDirectorNamed in SEC Form D filings
- Clay ThorpDirectorNamed in SEC Form D filings
- Frederic N. EshelmanDirectorNamed in SEC Form D filings
- Glenn A. MuirDirectorNamed in SEC Form D filings
- Gregory N. MossinghoffExecutive OfficerNamed in SEC Form D filings
Show all 15 people
- Jay StrumExecutive Officer, DirectorNamed in SEC Form D filings
- Mark A. VellecaExecutive Officer, DirectorNamed in SEC Form D filings
- Michael K GutchDirectorNamed in SEC Form D filings
- Norman SharplessDirectorNamed in SEC Form D filings
- Peter A. KolchinskyDirectorNamed in SEC Form D filings
- Ron A. LauferDirectorNamed in SEC Form D filings
- Seth K RudnickDirectorNamed in SEC Form D filings
- Thomas K LaundonExecutive OfficerNamed in SEC Form D filings
- Timothy N. SullivanDirectorNamed in SEC Form D filings
What it has protected
USPTO · 29 granted of 40- GrantedMorphic Forms Of Trilaciclib And Methods Of Manufacture ThereofUSPTOUS 12,168,666
- GrantedMorphic Forms Of G1T38 And Methods Of Manufacture ThereofUSPTOUS 12,139,494
- GrantedTransient Protection Of Normal Cells During ChemotherapyUSPTOUS 11,717,523
Show all 40 patent records
- Morphic Forms Of Trilaciclib And Methods Of Manufacture ThereofDec 17, 2024 · US 12,168,666Granted
- Morphic Forms Of G1T38 And Methods Of Manufacture ThereofNov 12, 2024 · US 12,139,494Granted
- Transient Protection Of Normal Cells During ChemotherapyAug 8, 2023 · US 11,717,523Granted
- Anti-neoplastic Combinations And Dosing Regimens Using CDK4/6 Inhibitor Compounds To Treat Rb-positive TumorsAug 3, 2023 · Application 17898196Pending
- Synthesis Of 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONEJul 25, 2023 · US 11,708,337Granted
- Hspc-sparing Treatments For Rb-positive Abnormal Cellular ProliferationMay 23, 2023 · US 11,654,148Granted
- SUBSTITUTED 1',2'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,4'-PYRIMIDO[5',4':4,5]PYRROLO[2,1-c][1,2,4]TRIAZIN]-3'-ONES AS CYCLIN-DEPENDENT KINASE INHIBITORSMay 9, 2023 · US 11,643,416Granted
- Synthesis Of N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINESApr 18, 2023 · US 11,629,150Granted
- Preservation Of Immune Response During Chemotherapy RegimensDec 20, 2022 · US 11,529,352Granted
- Anti-neoplastic Combinations And Dosing Regimens Using CDK4/6 Inhibitor Compounds To Treat Rb-positive TumorsSep 20, 2022 · US 11,446,295Granted
- Treatment Of Egfr-driven Cancer With Fewer Side EffectsJul 26, 2022 · US 11,395,821Granted
- G1T38 Superior Dosage RegimesJun 14, 2022 · US 11,357,779Granted
- Morphic Forms Of G1T38 And Methods Of Manufacture ThereofMar 1, 2022 · US 11,261,193Granted
- Cdk InhibitorsDec 23, 2021 · Application 17153516Pending
- Therapeutic Regimens For Treatment Of Cancer Using Eribulin And Selective CDK4/6 Inhibitor CombinationsSep 2, 2021 · Application 17315011Pending
- Treatment Of Rb-negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 InhibitorsAug 17, 2021 · US 11,090,306Granted
- Transient Protection Of Normal Cells During ChemotherapyJun 22, 2021 · US 11,040,042Granted
- Benzothiophene Estrogen Receptor Modulators To Treat Medical DisordersJun 10, 2021 · Application 17176962Pending
- Morphic Forms Of Trilaciclib And Methods Of Manufacture ThereofApr 27, 2021 · US 10,988,479Granted
- Benzothiophene Estrogen Receptor ModulatorsApr 20, 2021 · US 10,981,887Granted
- Transient Protection Of Normal Cells During ChemotherapyApr 6, 2021 · US 10,966,984Granted
- Transient Protection Of Hematopoietic Stem And Progenitor Cells Against Ionizing RadiationMar 18, 2021 · Application 17102311Pending
- Hspc-sparing Treatments For Rb-positive Abnormal Cellular ProliferationFeb 23, 2021 · US 10,925,878Granted
- Cdk InhibitorsFeb 23, 2021 · US 10,927,120Granted
- Pyrimidine-based Antiproliferative AgentsFeb 18, 2021 · Application 17088298Pending
- Treatment Of Cancers Having Driving Oncogenic MutationsFeb 4, 2021 · Application 17067549Pending
- Synthesis Of N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINESDec 15, 2020 · US 10,865,210Granted
- SUBSTITUTED DIHYDROPYRAZINO[1',2':1,5]PYRROLO[2,3-d]PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTSNov 10, 2020 · US 10,829,490Granted
- Highly Active Anti-neoplastic And Anti-proliferative AgentsNov 5, 2020 · Application 16926035Pending
- Heterocyclic Compounds For The Treatment Of Abnormal Cellular ProliferationOct 22, 2020 · Application 16918985Pending
- Antiproliferative Pyrimidine-based CompoundsSep 10, 2020 · Application 16877249Pending
- Pyrimidine-based Compounds For The Treatment Of CancerJul 30, 2020 · Application 16847426Pending
- Highly Active Anti-Neoplastic and Anti-Proliferative AgentsJul 14, 2020 · US 10,709,711Granted
- Cdk InhibitorsJun 30, 2020 · US 10,696,682Granted
- Transient Protection Of Normal Cells During ChemotherapyMay 26, 2020 · US 10,660,896Granted
- Antiproliferative Pyrimidine-based CompoundsMay 19, 2020 · US 10,654,831Granted
- Benzothiophene Estrogen Receptor ModulatorsApr 28, 2020 · US 10,633,362Granted
- Pyrimidine-based Compounds For The Treatment Of CancerApr 14, 2020 · US 10,618,905Granted
- Lactam Kinase InhibitorsNov 5, 2019 · US 10,464,940Granted
- Hspc-sparing Treatments For Rb-positive Abnormal Cellular ProliferationOct 8, 2019 · US 10,434,104Granted
Related companies, and why
- BIOSYMETRICS, INC.Similar federal contract value in Biotech · null in contracts
- CYTEGEN CORPSimilar federal contract value in Biotech · null in contracts
- BYOMASS, INC.Similar federal contract value in Biotech · null in contracts
- EXAI BIO, INC.Similar federal contract value in Biotech · null in contracts
- SPARIAN BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- INTRA THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .